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Summary Serum-free media conditioned by the androgen insensitive human prostate cancer cell line DU145
showed immunological transforming growth factor-a (TGFa) activity, as well as competing activity in
epidermal growth factor (EGF) radioreceptor assays (RRA). Furthermore, there were factors in the condi-
tioned media which inhibited and stimulated DNA synthesis by DU145 cells in a dose-dependent fashion.
Fractionation of the concentrated conditioned media by reverse-phase high performance liquid chromato-
graphy revealed several peaks containing EGF-like competitive activity only one of which demonstrated TGFa
activity. However, none of the peaks corresponded to immunoreactive EGF. Measurement of EGF receptors
on DU145 cells by competition and saturation analysis revealed high levels of receptors (mean ± s.d. =
2.5±1 x i05 surface receptors per cell) which were of high affinity (Kd±s.d. = 1.0±0.5 nmolI1). Although
DU145 cells express high levels of EGF receptors, DNA synthesis was only minimally affected by exogenous
EGF and TGFa.
The secretion of growth factors by some transformed cells is
thought to enable these cells to proliferate in low serum
concentrations as well as reducing the dependency upon
exogenous growth factors. One mechanism of transformation
is thought to involve cells being able to produce and respond
to growth factors (autocrine secretion), thus conferring a
growth advantage over other cells (Sporn & Todaro, 1980).
Transforming growth factors (TGFs) and other growth
factors have been implicated in the autocrine and/or para-
crine growth of tumour cells (Spom & Roberts, 1985). A lot
of interest has arisen in TGFs, as they are a family of
peptides which confer upon non-transformed cells several
properties associated with the transformed phenotype, such
as anchorage-independent growth in semisolid medium
(Brown & Blakely, 1984). TGFs are also unique in that their
expression is elevated in transformed cells (Marquardt et al.,
1983).
One class of TGFs is the TGFas. They are potent mito-
gens for a number of cell types and bind to and interact with
the epidermal growth factor (EGF) receptor (Massague,
1983). TGFas have significant sequence and structural hom-
ology to EGF and show a variety of biological actions
similar to EGF. Their biological activities when assayed in
cell culture systems are almost identical (Bascom et al., 1989),
although in some cases TGFs are more potent than EGF
(Stern et al., 1985; Ibbotson et al., 1986).
TGFas have been identified and purified from various
sources. Biologically active TGFaxs have been demonstrated
in crude or partially purified extracts prepared from rodent
and human mammary tumours and in the conditioned
medium (CM) obtained from several human cell lines
(Zwiebel et al., 1982; Brown & Blakely, 1984; Moses, 1984;
Salomon et al., 1984, 1986; Dickson et al., 1986; Perroteau et
al., 1986). In addition TGFa has been shown to be produced
by the hormone responsive LNCaP prostate cell line (Wilding
et al., 1989). However, it is not yet clear whether the hor-
mone independent prostate cancer cells secrete their own
TGFax as part of an autocrine regulatory mechanism. In the
present study we demonstrate that the hormone insensitive
human prostate cancer cell line DU145 produces bioactive
EGF-like molecules, which are immunologically related to
TGFa. We also examine the relationship between TGFa
production and the EGF receptor and the response of the
DU145 cells to the secretory products in the conditioned
media as well as to exogenous TGFa and EGF.
Materials and methods
Hormones andgrowthfactors
EGF from mouse submaxillary gland (receptor and tissue
culture grade), was purchased from Collaborative Research
(Universal Biologicals, St Ann's, London). Human EGF (or
urogastrone) was kindly donated by H. Gregory (ICI, Mac-
clesfield, UK). Rat TGF-1 (rTGF-1) was purchased from
Peninsula Laboratories Europe Ltd (St Helens, Merseyside,
UK) as part of a radioimmunoassay kit.
Cell culture
The prostatic human carcinoma cell lines DU145 was used in
all experiments. This cell line is an androgen independent
adenocarcinoma, originally isolated from a brain metastasis
(Stone et al., 1978) as was obtained from Dr D. Mickey
(Department of Urology, University of North Carolina,
USA).
The cells were maintained at 37°C in a humidified atmos-
phere of 95% air and 5% CO2 in 75 cm2 tissue culture flasks
(Corning, Staffordshire, UK) in serum free media. A serum
free DU145 cell line was developed for the purposes of this
study by repeated subculture at high density in RPMI 1640
(Flow Laboratories, Irvine, UK), supplemented with serum
free constituents: transferrin (10 mg 1-'), insulin (10 mg 1'),
hydrocortisone (1 mg' 1), phosphoethanolamine (50 g I1'),
3,3',5-tri-iodo-thyronine (0.04 nmol 1'; Sigma, Poole,
Dorset, UK), trace element mix (1 mg I'; Gibco, Irvine,
Scotland), L-glutamine (1%; Flow Laboratories) and peni-
cillin/streptomycin (0.8%; Gibco).
Preparation ofconditioned medium
Cells were grown to confluence in 75 cm2 tissue culture flasks
in serum free medium (SFM), the medium was changed once,
discarded and the cells were grown for a further 48 h in
20 ml of SFM. The conditioned media (CM) was clarified by
centrifugation (3,000 r.p.m. for 15 min) and filtered through
a 0.2 gm filter (Gelman Sciences Inc., Ann Arbor, Michigan,
USA). At this stage CM was stored at - 20°C until further
use. Pooled CM from 50 flasks (1 litre) were dialysed against
ammonium acetate (50 mmol 1-') in Spectrapor 3 dialysis
tubing at 4°C (mol. wt cut-off point 3,500; Spectrapor,
Pierce-Warriner, Chester, UK), after addition of phenyl-
methylsulphonyl fluoride (0.3 mmol 1-'; Sigma). The dialysed
CM was subsequently lyophilised to dryness. The lyophilised
material was reconstituted in 5 ml of PBS (0.02 M Na2
HPO4.2H2,NaH2PO4.2H20, 0.9% NaCl, pH 7.4) and clarified
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by centrifugation at 10,000g for 30 min.
Protein concentration was determined by the method of
Bradford (1976) using bovine serum albumin as standard.
3H-Thymidine incorporation
Subconfluent cells were rinsed in Dulbecco 'A' phosphate
buffered saline (PBS; Oxoid Ltd, UK), and once with 0.25%
trypsin and 0.2% EDTA (Gibco). The cells were incubated at
37°C for 5 min and subsequently resuspended in serum free
medium (SFM). Cell counts were determined in triplicate
dishes set up alongside the experimental dishes using a
haemocytometer chamber. Ten thousand cells were plated
overnight in SFM supplemented with 0.5% fetal calf serum
(FCS; Gibco) to assist plating, in 96-well plates (Cell-Cult).
The plating media was then replaced by SFM with either
EGF, TGFx or an aliquot of the CM for up to 72 h. After
the incubation period, methyl-3H-thymidine (37 kBq per well,
specific activity 75 GBq mmolh'; Amersham International
plc) was added in RPMI for at least 4 h. The medium in each
well was aspirated, resuspended before the addition of 10%
ice-cold trichloroacetic acid (TCA). The cells were harvested
2 h later on to filter mats (Skatron Combi Cell harvester) by
washing the well three times in water and then drying the
filter mats at 60°C for 30 min. Each disc of filter paper
containing the precipitable material was then counted in
scintillation fluid.
The growth factors EGF and TGFa were tested for an
effect on DNA synthesis of DU145 cells, over the range
0.01-10 nmol 1-. CM was also tested over the concentration
range 0.01-1,0001 g lyophilised CM ml-'.
EGFradioreceptor assay
Binding assays were carried out on DU145 monolayers, in
24-well plates (Cell-Cult) at a cell density of 2 x 105 cells per
well. Before addition of the binding medium, the SFM from
each well was aspirated and the cells and binding media were
cooled on ice to inhibit receptor internalisation. The cell
monolayers were then gently washed with Dulbecco 'A' PBS
and binding was initiated upon the addition of the appro-
priate concentration of '25I-EGF (Amersham; specific activity
4 GBqpg'), in 0.5ml of 0.02moll1' PBS (0.02mol Na2
HPO4.2H20 1-', 0.02 mol NaH2PO4.2H20 1-', 0.9% NaCl,
I g 1-' BSA) pH 7.4. Non-specific binding was determined in
the presence of 100-fold excess unlabelled EGF or CM in
RPMI 1640. All binding studies were carried out for 3 h at
4°C. Unbound '251-EGF was separated from cell bound 1251_
EGF by washing the cells 3 x in Dulbecco 'A' PBS. The
cells were subsequently solubilised with 1 ml 0.5 N NaOH,
for 15 min and transferred to plastic tubes for counting in a
gamma counter. Specfic binding was calculated as the differ-
ence between total binding and non-specific binding. Cell
numbers were determined from control wells (triplicate wells)
in which RPMI 1640 was added, without EGF.
Saturation and competition analysis
Evaluation of binding parameters were obtained by satura-
tion analysis over the range 0.05-8 nmolI" 1 25I-EGF with
or without excess unlabelled EGF. The dissociation constant
(Kd) and the number of binding sites (RT) were also measur-
ed by competition analysis with increasing concentrations of
EGF (0.01-200 nmol 1') and a constant amount of 12511
EGF (2 nmol 1-').
Radioreceptor competition assay (RRA)
DU145 cell monolayers were used as the source of EGF
receptors in the EGF-RRA, for analysis of competitive
activity in the CM. The amount of EGF equivalent units in
samples of CM was calculated by comparison with the com-
petition curves derived from unlabelled hEGF, with '25I-EGF
competing for EGF binding sites on DU145 cells. In this
assay the sensitivity for unlabelled mEGF, hEGF or TGFa is
approximately 0.12 ng per assay with 1 ng of 251I-EGF and
50% competition occurring at 0.6 ng per assay.
Reverse-phase highperformance liquidchromatography
The lyophilisate of CM stored at - 70°C was reconstituted in
5 ml of PBS. Trifluro acetic acid (TFA; 0.1%) was added to
an aliquot (10 mg) of the CM, vortexed and spun at 15,000
r.p.m. for 10 min. The soluble material was loaded on to a
Bio-Rad RP 304 C4 column (250 mm x 10 mm), with a slurry
packed guard column of the same material. The column was
equilibrated with 95% Buffer A (0.21tm filtered double dis-
tilled water (ddw), 0.1% TFA) and 5% Buffer B (20% ddw,
80% acetonitrile (MeCN), 0.085% TFA), and the sample
eluted with a linear gradient of 5-80% Buffer B, with a flow
rate of 0.5 ml min-' at 22°C. The absorbence of each fraction
was read at 280 nm with 1 ml fractions collected. Acetonitrile
was blown off each fraction under a stream of air, over 24 h,
and the remaining sample frozen to - 70°C, lyophilised to
dryness and reconstituted in 0.5 ml of 0.02M PBS with 1
g 1' BSA, pH 7.4. Every third fraction was analysed for
competitive activity in an EGF-RRA as previously described
and for hEGF and rTGF-I immunological activity by RIA.
Radioimmunoassaysfor TGFac and hEGF
The amount of immunoreactive TGFa and hEGF in samples
of CM and in the rHPLC fractions were determined using a
liquid-phase competitive RIA. Detection of TGFa was per-
formed using a commerical kit (Peninsula Laboratories Inc.)
with rTGF I as radioiodinated tracer and reference standard.
Antisera to the rTGF I were raised in rabbits and purchased
from Peninsula Laboratories Europe Ltd. The rabbit anti-rat
TGF I antiserum recognises both mouse and human TGFa
but does not cross react with either mouse or human EGF.
Half-maximal inhibition of binding of the 251I-peptide to the
antibody occurred at 100 pg per tube. EGF-life activity was
determined from the competition of hEGF for '251I-EGF
binding to anti hEGF serum. Briefly antiserum raised in
rabbits to purified hEGF (kindly provided by Dr H.
Gregory, ICI Macclesfield, UK) was incubated at 4°C with
1251I-EGF (10,000 c.p.m. per assay tube) and hEGF standards
(0-20 ng in triplicate) or CM samples. After 3 days donkey
anti-rabbit polyclonal IgG (Scottish Antibody Production
Unit, Carluke, UK) was added for 24 h at 4°C. The assay
tubes were then centrifuged at 3,000 r.p.m. for 30 min. The
supernatant was aspirated and the resultant radiolabel in the
pellets was determined by counting in a gamma counter.
Half-maximal competition was observed with 1-2 ng native
hEGF.
Data analysis
The computer analysis employed for competition and satura-
tion analysis was the weighted, non-linear least-squares curve
fitting program LIGAND (DeLean et al., 1978; Munson &
Rodbard, 1980). Data were analysed according to a model
for one or two binding sites. A model for two binding sites is
retained only when it fits the data significantly better
(P<0.05 partial F test) than a model for a single binding
site.
Statistical significance in the growth experiments was deter-
mined using a two-tailed Student's t test for comparison of
means.
Results
Production ofEGF-like competingfactors
To examine for the presence of specific EGF-like molecules
in the conditioned media from DU145 cells, increasing con-
centrations of CM were tested for their ability to compete
with '25I-EGF for binding to DUI45 cells (Figure 1). Growth
factors present in the CM inhibited '251-EGF in a doseTGFz IN PROSTATE CANCER 581
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Figure 1 Production of competitive EGF RRA activity from
medium conditioned by DU145 cells. Increasing concentrations
of DU145 conditioned media (CM) were assayed for EGF RRA
competitive activity. '25I-EGF 2 nmol 1I was incubated with or
without increasing concentrations of CM for 3 h at 4°C. Un-
bound, '25I-EGF was separated from cell bound '25I-EGF by
washing the cells 3 x in Dulbecco 'A' PBS. The cells were
subsequently solubilised with 1 ml 0.5 N NaOH and the radio-
activity remaining measured in a gamma counter. The amount of
EGF equivalent units in the CM was calculated by comparison to
the competition curves produced by unlabelled EGF with 1251_
EGF (inset). The experiment was repeated twice, and each data
point represents the mean ± s.d. (n = 6).
dependent fashion. By comparison to the competition curves
produced by unlabelled hEGF with 1251-EGF (inset of Figure
1), the amount of EGF eqivalent units in 1 litre of media
conditioned by DU145 cells was calculated to be approxi-
mately 30 ng.
Production ofimmunoreactive EGF and TGFa
Equivalent amounts of concentrated CM were assessed for
immunoreactivity using rTGF-1 and hEGF radioimmuno-
assays. The relative amounts of immunoreactive species pro-
duced by DU145 cells were compared with the levels of
biologically active EGF-like molecules that competed with
1251-EGF for binding to DU145 monolayers (Table I).
Approximately 20.3 ngl-I of immunoreactive TGFa was
produced by DU145 cells compared with 30 ng I' of EGF
equivalent molecules. As no EGF was detected when CM
was assayed for hEGF by RIA, then the remaining 32% of
bioactive EGF-like activity, not related immunlogically to
TGFx could not be attributed to the production of EGF.
Effect ofconditioned media on 3H-thymidine incorporation
Increasing concentrations of pooled and concentrated CM
produced from DU145 cells were added to DU145 cell
monolayers for up to 72 h and subsequently tested for their
effect on DNA synthesis. Table II shows that CM at 30 fg
ml-' induced a stimulation in thymidine incorporation at all
time points and for all but 72 h, this stimulation was signi-
ficant (P<0.05). However, the largest increase achieved was
after 24 h (Table II) and subsequently all experiments were
carried out at this time point. The results demonstrating the
optimal effect on DNA synthesis at 24 h are shown in Figure
2. Factors in the conditioned media had a biphasic effect on
DNA synthesis, with concentrations from 0.01 to ;Lg ml-'
Table I The presence of EGF receptor competing activity and
immunoreactive TGFa in the DU145 cells conditioned media
Assay Amount (nglt' CM)
RIA
hEGF 0.0± 0.0
rTGF-I 20.3± 2.4
RRA 30.0± 10.1
Table II Effect of DU145 CM (30 Agml-') on thymidine incorpora-
tion at different time points
Time 3H-Thymidine incorporation
(hours) (% ofcontrol±s.d.)
8 136±12 (P<0.05)
24 146±28 (P<0.001)
48 135±14 (P<0.05)
72 139±40 (P<0.05)
DU145cells(1.0 x 104cellsperwell)wereseededin96-wellplatesand
30fg ml-' ofCM was added for 8 (n = 6), 24 (n = 12), 48 (n = 6) and
72 h (n = 6) and 3H-thymidine for a further 4 h. Thymidine incorpora-
tion into DNAwasmeasured byprecipitating thecellularmaterial with
10% ice cold TCA. The data is expressed as the percentage of
3H-thymidine incorporated relativetotheuntreatedSFM control ± s.d.
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Figure 2 Dose-response effect of DUI45 CM on 3H-thymidine
incorporation in DU145 cells. DU145 cells (1.0 x l01 cells per
well) were seeded in 96-well plates and increasing concentrations
of CM (0.01-1,000ltgml-') added for 24 h and 3H-thymidine for
a further 4 h (37 Bq per well). After this time the amount of
3H-thymidine incorporated into DNA was measured by precipita-
ting the cellular material with 10% ice-cold TCA, added for 2 h.
The experiment was conducted over the concentration range
0.0I-I jgml-'I (n=6) and range 3-l1,OOgsgml ' (n= 12). The
data are expressed as the percentage of DH-thymidine incor-
porated relative to the untreated SFM control ± s.d.
having a marked inhibitory effect on incorporation of 3cH-
thymidine (50% inhibition relative to the untreated SFM
control where the control is expressed as 100%; P<0.001).
However, this inhibitory effect on DNA synthesis was over-
come by increasing the concentrations of CM: with a concen-
tration of30epsgdma',t H-thymidine incorporation was
increased by 46 ± 28% (P 0.05) relative to the SFM con-
trol. The marked decline in 3H-thymidine incorporation with
higher concentrations of CM was possibly due to dilution of
nutrients in the media.
rHPLCprofile ofconditioned media
Media conditioned by DU145 cells was chromatographed
using rHPLC and the fractions examined for immunological
rTGF 1, hEGF activity and EGF radioreceptor competitive
activity (Figure 3). Associated with the three major 280 nm
absorbence peaks (1 Au) in the middle of the gradient was a
minor peak of EGF radioreceptor competitive activity (20%
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Figure 3 Reverse-phase HPLC of concentrated DU145 CM.
Trifluroacetic acid (0.1%) was added to concentrated CM
(10mg). The soluble material was loaded on to a Bio-rad RP
304C4 column (250 mm x 1Omm) and subjected to rHPLC;
200pi aliquots of every third fraction was assayed for competitive
activity in an EGF RRA (- 0 -), and 100 LI aliquots assayed for
immunological hEGF and rTGF-1 activity by RIA (- ). Pro-
tein was determined by absorbence at 280 nm (-). The linear
MeCN gradient is marked by the continuous line.
competition). There were also two other major peaks of
competitive activity eluted at the beginning and end of the
run (40-50% competition). The only peak of immuno-
reactive rTGF I (fractions 12-19), which eluted with 25-35%
acetonitrile also demonstrated EGF-like competitive activity
(40% competition). All the fractions were tested for immuno-
reactive hEGF, but hEGF was not detected in any of the
rHPLC fractions.
The effect ofexogenous EGFand TGFcx on DNA synthesis
The effect of exogenous EGF and TGFoa on DNA synthesis
was measured by the incorporation of radiolabelled thymi-
dine (Figure 4). Preliminary studies were carried out to
examine the effect of EGF on DNA synthesis over a period
of up to 72 h. Maximum stimulation was achieved after 24 h
(data not shown) and subsequently all experiments were
therefore performed after 24 h. Both EGF and TGFx stimu-
lated 3H-thymidine incorporation into DU145 cells in a dose-
dependent manner. In the presence of 1 mmol EGF 1-'
thymidine incorporation was increased by 26 ± 13% (P<
0.001) whereas TGFa maximally stimulated thymidine incor-
poration at a concentration of 0.03 nmol 1- I by 17 ± 10%
(P<0.05). Similar results were obtained using cell numbers
as an index of proliferation (data not shown).
Saturation and competition studies
EGF receptor binding parameters (Kd and Bmax) were
estimated by competition and saturation analysis (Figure 5).
Competition studies were carried out with increasing concen-
trations of unlabelled EGF and a constant amount of label-
led ligand (2 nmol 1-'). Unlabelled EGF effectively competed
for '25I-EGF binding, with a dissociation constant (Kd) of
0.6 ± 0.5 nmol 1'. The results fitted significantly to a one site
receptor model as can be seen by the sigmoidal shape of the
curve (P<0.05) with (3 ± 1) x I05 receptor binding sites per
cell. Increasing concentrations of '25I-EGF saturated the
receptor binding sites (Figure 5). The results fitted signif-
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Figure 4 Dose-response effect of EGF and TGFa on DNA
synthesis in DU145 cells. Cells were seeded in 96-well plates
(1 x 104 cell per well), and after plating EGF or TOFai (0.01-10
nmol 1l ) was added for 24 h. 3H-Thymidine (37 Bq per well) was
then added for 4 h, the cells were trypinised and 10% ice-cold
TCA added for 2 h. The cells were then harvested on to filter
mats, dried and counted in scintillation fluid. Each data point
represents the mean ± s.d. (n = 24) of three separate experiments
and the data are normalised relative to the untreated SFM con-
trol (100%).
icantly to a one class of binding site (P<0.05) with an
estimated Kd value of 1 ± 0.5 nmol l-l and a Bmax of (2 +
0.8) x 105 per cell. Overall results from competition and
saturation analysis using the LIGAND curve fitting program
gave a Kd value of 1 ± 0.6nmoll' with (2.5 ± 1.2) x 105
receptor binding sites per cell.
Binding parameters were evaluated only by competition
and saturation analysis, due to the difficulty in estimating the
lowest ligand concentrations, which are unevenly 'weighted'
in Scatchard analysis (Bennett & Yamamura, 1985).
Discussion
The results of this study demonstrate that the human pros-
tatic cancer cell line DU145 produces molecules with TGFa-
like immunoreactivity and competitive activity in EGF radio-
receptor assays; this suggests that this cell line may be
involved in a TGFa-mediated autocrine loop. This is further
substantiated by the presence of high affinity receptors for
EGF on the cell surface. The DU145 cells in our experiments
also responded to exogenous EGF and TGFa by showing an
increase in 3H-thymidine in corporation. However, this re-
sponse was minimal which suggests that these cells may be
producing sufficient quantities of endogenous TGFas such
that they are generally insensitive to proliferation by exo-
genous growth factors. The presence or lack of minimal
proliferative response to exogenous growth factors has also
been observed with other cell lines producing TGFas
(Salomon et at., 1987; Verbeck et at., 1988; Valverius et at.,
1989; van Zoelen et at., 1987; Coffey et at., 1986), although
receptors are in most cases expressed. However, the presenceTGFa IN PROSTATE CANCER 583
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Figure 5 Competition and saturation analysis. Confluent DU145
monolayers were incubated with '25I-EGF (2 nmol l-') and in-
creasing concentrations of unlabelled EGF (0.01-100 nmol 1-')
for 3 h at 4C or with increasing doses of '25I-EGF (0.02-8 nmol
1-') and a constant amount of unlabelled EGF. The monolayers
were subsequently washed 3 x with Dulbecco 'A' PBS, and the
remaining radioactivity measured. The affinity constant and the
number of EGF binding sites were evaluated using the binding
program LIGAND. Three separate experiments were carried out
for each analysis.
of receptors does not necessarily mean that a cell responds to
a factor. In fact the loss of an EGF requirement after
malignant transformation is well described (Cherington et al.,
1979). Wollenberg et al. (1989) noted that rat hepatocytes
expressed receptors for EGF but that the high affinity recep-
tors were not involved in the proliferative response.
Media conditioned by DU145 cells had a significant stim-
ulatory and inhibitory effect on DNA synthesis, which was
dose responsive. Although other workers had examined the
relationship between immortal human prostate cell lines and
exogenous growth factors (Connolly & Rose, 1989; Wilding
et al., 1989), this is the first that an effect by CM was
reported in human prostate cancer cells. The biphasic effect
canhot, at this stage, be attributed solely to growth factor
production, nonetheless it is interesting to note that this cell
line is endogenously producing stimulatory and inhibitory
'factors' which are influencing the growth of these cells and
this warrants further investigation.
Using an immune-specific RIA, we demonstrated the pres-
ence of TGFa in medium conditioned by this cell line. How-
ever, stoichiometrically the level of immunologically related
TGFa was not equivalent to the amount of EGF-like com-
petitive activity which suggests that this cell line is producing
forms of EGF related polypeptides distinct immunologically
from TGFa and hEGF. This was further verified using a
HPLC as we identified several molecular forms of EGF
receptor binding polypeptides in medium conditioned by
DU145 cells. Only one of three peaks demonstrated TGFx
immunoreactivity and none were related to hEGF. It is
interesting to note that many other types of cancer cells
produce several molecular forms related to TGFa (Dickson
et al., 1986; Stromberg et al., 1986; Salomon et al., 1987).
The TGFa related molecular species produced by the DU145
prostate cell line may comprise the precursor form of TGFx
or intermediate forms; further studies are required to distin-
guish between these possibilities. Nevertheless, this raises the
possibility that it may be possible for a cell to make subtle
changes in response by producing different molecular forms
of TGFa. We conclude, therefore, that DU145 by producing
its own growth factors has little or no need for exogenous
EGF and TGFa; the levels of growth factors produced may
be auto-stimulatory, although this remains to be determined.
The authors wish to thank Dr J. Sharkey for his assistance with data
analysis and Dr M. Collins for comments on the manuscript.
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